DURECT Corporation to Participate in Fireside Chat at H.C. Wainwright 4th Annual NASH Investor Conference
DURECT Corporation (Nasdaq: DRRX) announced participation in a fireside chat on October 5, 2020, from 2:30 p.m. to 3:00 p.m. EDT. Key executives, including President and CEO James E. Brown, CFO Michael H. Arenberg, and EVP of R&D Dr. WeiQi Lin, will join host Ed Arce from H. C. Wainwright. Investors can view the live webcast on DURECT's homepage under the 'Investors' tab or directly here. The company focuses on developing therapies for liver diseases and acute organ injury.
- None.
- None.
CUPERTINO, Calif., Sept. 30, 2020 /PRNewswire/ -- DURECT Corporation (Nasdaq: DRRX) announced today that James E. Brown, President, CEO, Michael H. Arenberg, Chief Financial Officer, and Dr. WeiQi Lin, Executive Vice President of R&D will be participating in a fireside chat hosted by Ed Arce of H. C. Wainwright on Monday, October 5, 2020 from 2:30 p.m. to 3:00 p.m. EDT / 11:30 a.m. to noon PDT.
A live webcast of the presentation will be available by accessing https://journey.ct.events/view/e7ded313-1d06-476a-971c-b76dce8a6457
The live webcast of the presentation will also be available by accessing DURECT's homepage at www.durect.com and clicking on the "Investors" tab.
About DURECT Corporation
DURECT is a biopharmaceutical company committed to transforming the treatment of acute organ injury and chronic liver diseases by advancing novel and potentially lifesaving therapies based on its endogenous epigenetic regulator program. DUR-928, the company's lead drug candidate is in clinical development for the potential treatment of alcoholic hepatitis (AH), COVID-19 patients with acute liver or kidney injury, and nonalcoholic steatohepatitis (NASH). DUR-928 epigenetically modulates the expression of multiple clusters of master genes that are involved in many important cell signaling pathways, through which it stabilizes mitochondria, reduces lipotoxicity, regulates inflammatory or stress responses, and promotes cell survival. DURECT's proprietary drug delivery technologies are designed to enable new indications and enhanced attributes for small-molecule and biologic drugs. One late-stage product candidate in this category is POSIMIR® (bupivacaine extended-release solution), an investigational locally-acting, non-opioid analgesic intended to provide up to three days of continuous pain relief after surgery. For more information about DURECT, please visit www.durect.com and follow us on Twitter https://twitter.com/DURECTCorp.
DURECT Forward-Looking Statement
The statements in this press release regarding clinical development plans for DUR-928, including the potential use of DUR-928 to treat COVID-19 patients with liver or kidney injury, the potential use of DUR-928 to treat acute organ injuries, such as AH, and chronic liver diseases, such as NASH, and the potential use of POSIMIR to provide pain relief after surgery are forward-looking statements involving risks and uncertainties that can cause actual results to differ materially from those in such forward-looking statements. Potential risks and uncertainties include, but are not limited to, the risks that the clinical trial of DUR-928 in COVID-19 patients is delayed or stopped because of changes to the standard of care, the availability of alternative therapies, required protocol changes or lack of available patients, the risk that future clinical trials of DUR-928 are not started when anticipated, take longer to conduct than anticipated, do not confirm the results from earlier clinical or pre-clinical trials, or do not demonstrate the safety or efficacy of DUR-928 in a statistically significant manner, the risk that the FDA will not approve POSIMIR or approve POSIMIR with a limited label, the risk that additional time and resources may be required for development, testing and regulatory approval of DUR-928 or the Company's other product candidates, potential adverse effects arising from the testing or use of our drug candidates, our potential failure to maintain our collaborative agreements with third parties and risks related to our ability to obtain capital to fund operations and expenses. Further information regarding these and other risks is included in DURECT's Form 10-Q filed on August 4, 2020 under the heading "Risk Factors."
NOTE: POSIMIR® and SABER® are trademarks of DURECT Corporation. Other referenced trademarks belong to their respective owners. DUR-928 and POSIMIR are investigational drug candidates under development and have not been approved for commercialization by the U.S. Food and Drug Administration or other health authorities for any indication.
View original content:http://www.prnewswire.com/news-releases/durect-corporation-to-participate-in-fireside-chat-at-hc-wainwright-4th-annual-nash-investor-conference-301142361.html
SOURCE DURECT Corporation
FAQ
What event will DURECT Corporation's executives participate in on October 5, 2020?
Who are the key executives participating in the DURECT Corporation fireside chat?
What is the time for DURECT Corporation's fireside chat on October 5, 2020?
How can I access the DURECT Corporation fireside chat webcast?
What is the focus of DURECT Corporation's drug development?
